Morphologic Changes in Ovarian Carcinoma After Neoadjuvant Chemotherapy: Report of a Case Showing Extensive Clear Cell Changes Mimicking Clear Cell Carcinoma

被引:11
作者
Chew, Ivy [2 ]
Soslow, Robert A.
Park, Kay J. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
[2] Singapore Gen Hosp, Dept Pathol, New York, NY USA
关键词
Ovarian carcinoma; Clear cell carcinoma; Morphologic changes; Neoadjuvant chemotherapy; SEROUS CARCINOMA; REGRESSION; SURVIVAL; CANCER;
D O I
10.1097/PGP.0b013e3181a071b5
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Neoadjuvant chemotherapy followed by interval debulking has become an alternative treatment option for patients with advanced-stage ovarian cancer. The effects of chemotherapy on the histologic features of the tumor have not been well described for ovarian carcinoma, especially related to changes that significantly alter the appearance of the tumor. In this study, we describe a case of ovarian serous carcinoma status-post neoadjuvant chemotherapy that showed exuberant clear cell/foamy change. This unusual morphology raised the possibility of a mixed epithelial carcinoma or a secondary malignancy. Immunohistochemical stains were performed to help distinguish whether the tumor was a serous carcinoma with chemotherapy-induced clear cell change or a distinct clear cell carcinoma of ovarian or extraovarian origin. The clear cell and conventional serous components showed diffuse positivity for CK7, CA125, and ER; however, only the clear cell component was positive for hepatocyte nuclear factor-1 beta and only the conventional serous component was positive for WT1. Although there was a slight discrepancy in the staining patterns, given the lack of other typical histologic features of clear cell carcinoma, the unusual clear cell morphology was most likely the result of chemotherapy-induced changes.
引用
收藏
页码:442 / 446
页数:5
相关论文
共 17 条
[1]   Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy [J].
Becker, K ;
Mueller, JD ;
Schulmacher, C ;
Ott, K ;
Fink, U ;
Busch, R ;
Böttcher, K ;
Siewert, JR ;
Höfler, H .
CANCER, 2003, 98 (07) :1521-1530
[2]   Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction [J].
Bristow, Robert E. ;
Eisenhauer, Eric L. ;
Santillan, Antonio ;
Chi, Dennis S. .
GYNECOLOGIC ONCOLOGY, 2007, 104 (02) :480-490
[3]  
Carder P, 1999, HISTOPATHOLOGY, V35, P584
[4]   Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease [J].
Hou, June Y. ;
Kelly, Michael G. ;
Yu, Herbert ;
McAlpine, Jessica N. ;
Azodi, Masoud ;
Rutherford, Thomas J. ;
Schwartz, Peter E. .
GYNECOLOGIC ONCOLOGY, 2007, 105 (01) :211-217
[5]   Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary [J].
Kato, N ;
Sasou, S ;
Motoyama, T .
MODERN PATHOLOGY, 2006, 19 (01) :83-89
[6]   THE EFFECTS OF HORMONAL AND CHEMOTHERAPY ON TUMORAL AND NONNEOPLASTIC BREAST-TISSUE [J].
KENNEDY, S ;
MERINO, MJ ;
SWAIN, SM ;
LIPPMAN, ME .
HUMAN PATHOLOGY, 1990, 21 (02) :192-198
[7]  
Köbel M, 2009, AM J SURG PATHOL, V33, P14, DOI 10.1097/PAS.0b013e3181788546
[8]  
Kuhn W, 2001, CANCER-AM CANCER SOC, V92, P2585, DOI 10.1002/1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO
[9]  
2-#
[10]   Grading ovarian serous carcinoma using a two-tier system [J].
Malpica, A ;
Deavers, MT ;
Lu, K ;
Bodurka, DC ;
Atkinson, EN ;
Gershenson, DM ;
Silva, EG .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (04) :496-504